Matthijs van Luin

ORCID: 0000-0001-8409-9316
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV/AIDS drug development and treatment
  • Pneumocystis jirovecii pneumonia detection and treatment
  • HIV/AIDS Research and Interventions
  • HIV Research and Treatment
  • Acute Lymphoblastic Leukemia research
  • HIV-related health complications and treatments
  • Inflammatory Bowel Disease
  • Antibiotics Pharmacokinetics and Efficacy
  • Pharmacological Effects and Toxicity Studies
  • Hepatitis C virus research
  • Cystic Fibrosis Research Advances
  • Drug-Induced Adverse Reactions
  • Pregnancy and Medication Impact
  • Adrenal Hormones and Disorders
  • Autoimmune and Inflammatory Disorders Research
  • Pneumonia and Respiratory Infections
  • Adolescent and Pediatric Healthcare
  • Pharmaceutical studies and practices
  • Chronic Lymphocytic Leukemia Research
  • Systemic Lupus Erythematosus Research
  • Hepatitis B Virus Studies
  • Medication Adherence and Compliance
  • Inhalation and Respiratory Drug Delivery
  • Cholinesterase and Neurodegenerative Diseases
  • Transplantation: Methods and Outcomes

University Medical Center Utrecht
2021-2025

Meander Medisch Centrum
2024-2025

Utrecht University
2021-2024

Rijnstate Hospital
2009-2020

Royal Dutch Pharmacists Association
2016

Radboud University Nijmegen
2008-2014

Radboud University Medical Center
2008-2014

Zorggroep Kans
2010-2013

OLVG
2010

Nijmegen Institute for Scientist Practitioners in Addiction
2010

A wide range of effective antiretroviral therapy (ART) regimens with favourable side effects are available. More than 70% HIV care costs in the Netherlands attributed to ART. We developed an ART algorithm proactively switch virologically suppressed individuals a more cost-effective treatment. This prospective study implemented our two large Dutch clinics, where pharmacist screened for 1 year. Individuals were considered suitable if their current exceeded €600 per month, considering renal...

10.1093/jac/dkaf117 article EN cc-by Journal of Antimicrobial Chemotherapy 2025-04-12

Background: Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in persons with Cystic Fibrosis (CF). Nebulization tobramycin or colistin mostly applied but has a significant treatment burden. Dry powder (DP) inhalation may offer an attractive alternative. The aim of this study was to assess local tolerability and systemic pharmacokinetic parameters increasing doses dry tobramycin. Methods: This evaluation pilot DP three different inhaled through Cyclops (30, 60, 120 mg) ten...

10.3390/pharmaceutics17030347 article EN cc-by Pharmaceutics 2025-03-07

Summary Background Tioguanine (or thioguanine) is an alternative drug for IBD patients who fail prior conventional immunomodulating therapy. Aim To report effectiveness, safety and therapeutic monitoring in a cohort of with prolonged tioguanine maintenance Methods In this nationwide, multicentre study, medical records tioguanine‐ using were retrospectively reviewed. Response to therapy was defined as clinical effectiveness without (re)initiation corticosteroids, concurrent biological or...

10.1111/apt.15280 article EN cc-by-nc Alimentary Pharmacology & Therapeutics 2019-05-16

HIV-infected travellers frequently use atovaquone/proguanil as malaria prophylaxis. We compared pharmacokinetics between healthy volunteers and patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)0-->t for atovaquone relative to was 0.25 (0.16-0.38), 0.26 (0.17-0.41) 0.54 (0.35-0.83) on atazanavir/ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%)....

10.1097/qad.0b013e3283389129 article EN AIDS 2010-03-18

To establish whether efavirenz dose reduction in patients with high plasma concentrations prevents toxicity-induced discontinuations.HIV-infected a concentration (>or=4.0 mg/L) while using 600 mg once daily as part of their highly active antiretroviral therapy regimen were selected from the AIDS Therapy Evaluation The Netherlands cohort study. These classified into 2 groups. reduced-dose group contained all who underwent after measurement; standard-dose consisted had no reduction....

10.1097/qai.0b013e3181b061e6 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2009-09-22

Antiretroviral therapy (ART), which is increasingly used by people with HIV, accounts for significant care costs, particularly because of single-tablet regimens (STRs). This study explored de-simplification to a two-tablet regimen (TTR) cost reduction. The objectives this were: (1) acceptance de-simplification, (2) patient-reported outcomes, and (3) savings.

10.1111/hiv.13655 article EN cc-by-nc-nd HIV Medicine 2024-05-07

Therapeutic drug monitoring is frequently used in several European countries, and international guidelines recommend it selected cases. We discuss the main arguments for against therapeutic HIV infection.Accumulating evidence favours use of management concentration-related toxicities. Interindividual variability pharmacokinetics antiretroviral drugs at least partially caused by genetic polymorphisms. Additionally, body weight, sex ethnicity have been identified as independent predictors...

10.1097/coh.0b013e3282f82c1b article EN Current Opinion in HIV and AIDS 2008-05-01

The authors studied the effect of raltegravir on pharmacokinetics antiepileptic agent lamotrigine. Twelve healthy volunteers (group A) received 400 mg twice daily from days 1 to 5. On day 4, a single dose 100 lamotrigine was administered. After washout period, participants second but now without (day 32). In group B, 12 same treatment as in A reverse order. 4 and 32, 48-hour pharmacokinetic curves were drawn. Geometric mean ratios (+90% confidence intervals [CIs]) area under plasma...

10.1177/0091270009345689 article EN The Journal of Clinical Pharmacology 2009-08-29

Valproic acid (VPA) is an effective antiepileptic drug and mood stabilizer. A key characteristic of VPA its high saturable protein binding at higher concentrations. Although the unbound concentration responsible for pharmacological activity, total concentrations are monitored in routine clinical practice. Therapeutic monitoring (TDM) recommended specific situations. The goal this study was to evaluate TDM requests practice.All our laboratory 2014 2015 were evaluated retrospectively. In...

10.1097/ftd.0000000000000405 article EN Therapeutic Drug Monitoring 2017-04-21

Co1nflicting data exist regarding the effect of efavirenz (EFV) plasma concentrations on central nervous system (CNS) toxicity. We aimed to determine whether patients with high EFV have an increased likelihood toxicity-driven discontinuations.EFV were measured from in EuroSIDA study starting after 1 January 1999. Patients a concentration available divided into those that discontinued because any toxicity or by choice patient physician within 2 years (TOXPC group) and continued for > = (no...

10.1177/135965350901400116 article EN Antiviral Therapy 2009-01-01

A 46-year old man with a chronic hepatitis C virus infection received triple therapy ribavirin, pegylated interferon and telaprevir. The patient also simvastatin. One month after starting the antiviral therapy, was admitted to hospital because he developed rhabdomyolysis. At admission simvastatin all drugs were discontinued toxicity due drug-drug interaction suspected. creatine kinase peaked at 62,246 IU/L treated intravenous normal saline. patient’s renal function remained unaffected....

10.1016/s1665-2681(19)30853-1 article EN cc-by-nc-nd Annals of Hepatology 2014-07-01

ObjectivesTo manage the interaction between fosamprenavir/ritonavir and posaconazole, we hypothesized that ritonavir can be replaced by posaconazole as an alternative booster of fosamprenavir with no significant influence on pharmacokinetics.

10.1093/jac/dkq280 article EN Journal of Antimicrobial Chemotherapy 2010-07-28

To evaluate the potential drug-drug interaction between raltegravir and pravastatin.This was an open-label, randomized, 3-period, cross-over, single-centre trial in 24 healthy volunteers. Subjects received following treatments: pravastatin 40 mg every day for 4 days, 400 twice a + days. The treatments were separated by washout periods of 10 On each treatment period, blood samples pharmacokinetics collected throughout 24-hour period.Geometric mean ratios (90% confidence interval) versus alone...

10.1097/qai.0b013e3181d9a354 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2010-04-15

There is an ongoing debate regarding whether low-level viremia (LLV), in particular persistent LLV, during HIV treatment with optimal adherence originates from viral replication, production, or both. We performed observational study 30 individuals LLV who switched to a boosted darunavir (DRV)-based therapy. In-depth virological analyses were used characterize the population and (activity) of reservoir. Immune activation was examined using cell-bound soluble markers. The primary outcome...

10.3390/v16020182 article EN cc-by Viruses 2024-01-25

High variability in tacrolimus pharmacokinetics directly after lung transplantation (LuTx) may increase the risk for acute kidney injury (AKI) and transplant rejection. The primary objective was to compare pharmacokinetic patients receiving orally versus intravenously early LuTx.

10.1007/s40262-024-01368-1 article EN cc-by-nc Clinical Pharmacokinetics 2024-04-06

Abstract Background Low-dose weekly methotrexate (MTX) is the mainstay of treatment in juvenile idiopathic arthritis. Unfortunately, a substantial part patients has insufficient efficacy MTX. A potential cause this inadequate response suboptimal drug adherence. The aim study was to assess MTX adherence arthritis by quantification concentrations plasma. Secondly, association between and either self-reported issues, or concomitant use biologics examined. Methods This retrospective,...

10.1186/s12969-024-00988-y article EN cc-by Pediatric Rheumatology 2024-05-07

Vancomycin has been reported to cause vancomycin flushing reaction (VFR), a hypersensitivity that mostly occurs after intravenous administration. The incidence of VFR in patient receiving intraperitoneal is rare. We report case female peritoneal dialysis (PD) with PD-related peritonitis who developed administration 2000 mg vancomycin. Seventy-five minutes instillation, she flushing, pruritic erythema on the upper body and swelling lips. Blood results revealed plasma concentration 54.8 mg/L...

10.1177/08968608231199735 article EN cc-by Peritoneal Dialysis International 2023-09-25

Cefiderocol is a broad-spectrum cephalosporin antibiotic and indicated in patients with difficult-to-treat Gram-negative bacterial infections. applied as 2-4-times daily prolonged 3-h infusion. The therapeutic target of cefiderocol suggests that continuous infusion (CI) may be advantageous, since it more likely to achieve 100% time the unbound concentration above minimal inhibitory (MIC). However, limited information on CI has been assessed. We present case critically ill 37-year-old woman...

10.1111/bcp.15901 article EN cc-by-nc British Journal of Clinical Pharmacology 2023-09-07

Therapeutic drug monitoring (TDM) is recommended in several international HIV treatment guidelines. The adherence of clinicians to these recommendations unknown. authors evaluated the Dutch TDM guideline 2005.From ATHENA cohort study, three scenarios were selected for which TDM: 1) start a combination lopinavir/ritonavir + efavirenz or nevirapine (drug-drug interaction); 2) (routine TDM); and 3) use nelfinavir during pregnancy. For each scenario, we determined proportion patients whom was...

10.1097/ftd.0b013e318205b81d article EN Therapeutic Drug Monitoring 2010-12-31

The effect of the Dutch nationwide adjustment reducing 6-thioguanine nucleotide (6-TGN) target values (from 600-1200 to 320-630 pmol/8 × 108 red blood cells [RBC]) on toxicity and clinical outcome thiopurine treatment in patients with inflammatory bowel disease has not yet been established. Therefore, authors determined incidence toxicity-induced discontinuations efficacy at both concentrations.This retrospective study was performed treated azathioprine or mercaptopurine. Two groups were...

10.1111/bcp.15315 article EN British Journal of Clinical Pharmacology 2022-03-16

Abstract Background For the analysis of 6-thioguanine nucleotides (6-TGN) and 6-methylmercaptopurine ribonucleotides (6-MMPR), no external quality assessment scheme (EQAS) is currently available control samples can be made because absence pure substances. An experimental design tested to compare laboratory analytical results. Methods In this EQAS, participating laboratories were asked select patient from their routine exchange these with a coupled laboratory. Because large differences in...

10.1515/cclm-2018-0116 article EN Clinical Chemistry and Laboratory Medicine (CCLM) 2018-08-15
Coming Soon ...